Concepedia

Nitya Nair

NN

19

Publications

1.7K

Citations

16

H-Index

1993

Active since

Affiliations

Johns Hopkins University(Current)

Stanford University

Aduro BioTech (United States)

Johns Hopkins Medicine

University of Chicago

Nitya Nair is an author at Johns Hopkins University specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1993–2022

19

Publications

19

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Funda Meric‐Bernstam, Randy F. Sweis, F. Stephen Hodi et al. · Clinical Cancer Research · 2021 · 328 citations · Full text

Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization

Evan W. Newell, Natalia Sigal, Nitya Nair et al. · Nature Biotechnology · 2013 · 299 citations · Full text

, , +8

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper et al. · Clinical Cancer Research · 2022 · 205 citations · Full text

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric‐Bernstam, Shahneen Sandhu, Omid Hamid et al. · Journal of Clinical Oncology · 2019 · 186 citations

, , +21

Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Raffit Hassan, Evan Alley, Hedy L. Kindler et al. · Clinical Cancer Research · 2019 · 121 citations · Full text

Rows per page

1–5 of 19